The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Published:2013 Issue:1 Volume:12 Page:70
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Ring Arne,Brand Tobias,Macha Sreeraj,Breithaupt-Groegler Kerstin,Simons Gudrun,Walter Beate,Woerle Hans J,Broedl Uli C

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Reference37 articles.

1. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

2. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

3. Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

4. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

5. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-02

2. Dapagliflozin Pretreatment Prevents Cardiac Electrophysiological Changes in a Diet and Streptozotocin Induction of Type 2 Diabetes in Rats: A Potential New First-Line?;Journal of Experimental Pharmacology;2024-03

3. Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters;Reviews in Cardiovascular Medicine;2024-02-18

4. Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: A double-blind, randomized, placebo-controlled trial;2024-02-13

5. Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview;Frontiers in Cardiovascular Medicine;2023-05-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3